Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data ...

Veracyte (NASDAQ:VCYT) and Decipher Biosciences (DECI), commercial-stage precision oncology company focused on urologic cancers, inked a definitive acquisition agreement under which former will ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the ...

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...

Veracyte VCYT is making solid progress in its Afirma business line. The company’s Decipher franchise continues to be a strong tailwind, with remarkable test volume growth. Sound financial health also ...

Jonathan Wygant, VP at Veracyte (NASDAQ:VCYT), executed a substantial insider sell on November 12, according to an SEC filing. What Happened: A Form 4 filing with the U.S. Securities and Exchange ...

Veracyte’s VCYT shares have surged 30.9% in the past year, showing impressive momentum. It has significantly outperformed the industry’s 13.1% decline and the S&P 500 composite’s 12.1% gain. Presently ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...

Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain. With a ...